Integrity,Innovation,Reliability,Responsibility

Final Analysis Results of Hinova Pharmaceuticals' Phase IIa Clinical Trial for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Released!

Time:2026-06-16 Source:海创药业 Hits:111

The Phase IIa clinical trial of HP515 tablets, a Class 1 innovative drug independently developed by Hinova Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as non-alcoholic steatohepatitis [NASH]), has achieved its primary endpoint and key secondary endpoints in the final analysis.


Phase IIa Clinical Trial Results

  • Significant Reduction in Hepatic Fat Content:


The primary efficacy endpoint of this study was the percentage change from baseline in week-12 liver fat fraction (LFC) as measured by magnetic resonance proton density fat fraction (MRI-PDFF) and assessed by an independent third party. The results showed that the mean LFC at week 12 decreased by more than 50% across all HP515 tablet dosage groups (40 mg, 50 mg, and 60 mg) once daily, compared to only a 3.5% reduction in the placebo group. The differences between each drug group and the placebo group were all statistically significant (P<0.001). Moreover, the proportions of patients achieving LFC reductions from baseline of ≥30% and ≥50% at week 12 were significantly higher in each drug group compared to the placebo group (P<0.001).


  • Significant Improvement in Dyslipidemia:

Compared with the placebo group, HP515 tablet treatment for 12 weeks significantly improved low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), triglycerides (TG), and small dense low-density lipoprotein cholesterol (sd-LDL-C) (P<0.001).


  • Excellent Safety Profile:


HP515 tablets were generally well-tolerated. With the exception of one grade 3 adverse event (AE) unrelated to the drug, all other AEs were grade 1–2. The distribution of AEs was balanced across all groups (including the placebo group), with no serious adverse events (SAEs) reported and no drug-related adverse events leading to discontinuation. The overall safety profile was similar to that of other reported THR-β agonists.


In summary, the trial results demonstrate that HP515 tablets can significantly improve hepatic fat metabolism while also improving dyslipidemia, with an overall favorable safety profile.


About HP515

HP515 tablets are an oral, highly selective, and highly potent THR-β (thyroid hormone receptor beta) agonist independently developed by the Company. HP515 tablets directly act on THR-β to activate downstream gene transcription, improving metabolic dysfunction-associated steatohepatitis by enhancing hepatocellular lipid metabolism, promoting hepatic fat metabolism, and reducing lipotoxicity. As of the date of this announcement, no products targeting the same indication have been approved for marketing in China.


HP515 received approval from China's National Medical Products Administration (NMPA) in August 2024 for the treatment of metabolic steatohepatitis (MASH), and received approval from the U.S. Food and Drug Administration (FDA) in September 2024 for the treatment of MASH. The Company has completed the Phase I clinical trial of HP515, the results of which demonstrated that HP515 met expectations in terms of safety, tolerability, pharmacokinetics, and pharmacodynamics.


Phase IIa Clinical Trial


The HP515 Phase IIa clinical trial is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase IIa clinical trial in participants with metabolic dysfunction-associated fatty liver disease (MASLD). The purpose of the trial is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of HP515 tablets in participants with MASLD. The primary efficacy endpoint is the percentage change from baseline in week-12 liver fat fraction as measured by MRI-PDFF and assessed by an independent third party. A total of 99 MASLD participants who met the eligibility criteria were enrolled and randomized to three HP515 treatment groups (40 mg, 50 mg, 60 mg) and the placebo group, with treatment continued for 12 weeks. Participants underwent multiple safety and efficacy assessments during the treatment period. All participants have now completed the clinical trial, and the database has been locked. The key statistical results of the final analysis have been completed, yielding positive results.


Introduction to the MASH Indication


Metabolic dysfunction-associated fatty liver disease (MASLD, or MAFLD) is a chronic progressive liver disease caused by nutritional excess and insulin resistance in genetically susceptible individuals. The disease spectrum includes metabolic dysfunction-associated fatty liver, metabolic dysfunction-associated steatohepatitis, and related fibrosis and cirrhosis [1]. MASH is a more severe subtype of MASLD and is a potentially progressive liver disease characterized by hepatomegaly, hepatic steatosis, increased inflammatory response, and increased hepatic fibrosis, which may further progress to cirrhosis, hepatocellular carcinoma, and death [2]. MASLD is the most common chronic liver disease globally, with a prevalence of 6.3%–45% in the general adult population, of which 10%–30% is MASH. The prevalence of MASLD in China and most Asian countries is at a moderate-to-high level (>25%). The global prevalence of MASH is 3%–5% [3], with a mortality rate of 25.56%, and the prevalence of MASH in US adults may reach 5.8% [5]. The prevalence trends parallel those of obesity, type 2 diabetes, and metabolic syndrome. It is estimated that by 2030, the number of MASH patients in China will reach 48.3 million [4], and the number of MASH patients in the US will reach 27 million [5].


According to Frost & Sullivan data, the global MASH market is projected to reach USD 32.2 billion by 2030, and the China MASH drug market is expected to reach RMB 35.5 billion by 2030 [6].


References

[1] Chinese Medical Association Hepatology Branch, Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Non-Alcoholic) Steatotic Liver Disease (2024 Edition)

[2] Zobair M. Younossi. Non-alcoholic fatty liver disease – A global public health perspective [J]. Journal of Hepatology, 2019, vol.70:531–544.

[3] YOUNOSSI ZM, KOEING AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016, 64(1):83-84.

[4] Yaorong Consulting, "Analysis Report on Market and R&D Landscape in the NASH Treatment Field"

[5] Le P, Tatar M, Dasarathy S, et al. Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1)

[6] Frost & Sullivan data cited in Kelun Pharmaceutical News: https://mp.weixin.qq.com/s/_q0cA4NMDUWQCsyQpUoEJg


Disclaimer:

1. This article is intended solely to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not promotional material. Hinova Pharmaceuticals does not make any recommendation, commitment, or guarantee regarding any drug or indication.

2. The information contained herein is derived from relevant research reports and clinical data and is for reference only. Please follow the guidance of physicians or other qualified healthcare professionals.

3. Any information involving unapproved products refers to assets still in development or clinical trials and involves uncertainties. Final outcomes are subject to approval by the National Medical Products Administration.